Pharmaceutical company Abbvie had its shares drop about 3% last week after California’s insurance commissioner Dave Jones sued the company, alleging Abbvie has been providing kickbacks in the form of nursing support and insurance assistance to prompt doctors to write prescriptions for its arthritis drug Humira.
Mr. Jones, who filed a complaint in Alameda County Superior Court, alleges the company’s “Ambassador” program was intended to “keep patients on a dangerous drug at any cost.”
AbbVie claimed in a statement that it “operates in compliance with the many state and federal laws that govern interactions with healthcare providers and patients.”
Credit Suisse analysts said that the lawsuit could have extensive repercussions in the drug industry since the kickback practices “are similar to what other biopharma companies have also used to help patients start and stay on medications that their doctor prescribes.”
Full Content: Bloomberg & The Wall Street Journal
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI